References: Hair growth and hair loss
Obstet Gynecol. 1978 Sep;52(3):349-54.
The use of Adriamycin and mehtotrexate in carcinoma of the cervix. The development of a safe effective regimen.
Guthrie D, Way S.
The results of treating 59 patients with advanced carcinoma of the cervix with Adriamycin and methotrexate are given. Five combinations of the two cytotoxic drugs have been evaluated, differing only with regard to the methotrexate. One particular regimen has been shown to be effective with a relatively high remission rate coupled with a low rate of side effects.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=309102&dopt=Abstract
Cancer Chemother Pharmacol. 1986;18 Suppl 2:S10-2.
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Wiltshaw E, Westbury G, Harmer C, McKinna A, Fisher C.
Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients. All these patients treated at The Royal Marsden Hospital plus 30 more (total 67) have now been analysed. Single doses of 5 or 8 g/m2 ifosfamide were given over 24 h by infusion in dextrose saline together with 400 mg/m2 or 600 mg/m2, respectively, of mesnum every 4 h to give a total of 9 doses. A diuresis of 200 ml/hour was maintained during therapy. Treatment was repeated 3-weekly. CR was seen in 6 and PR in 10 patients. More recently doxorubicin was added to ifosfamide therapy in an attempt to improve on these results. At first only 20 mg/m2 doxorubicin was given but this was escalated to 40 mg/m2 and 60 mg/m2. Mesna has been given in higher dosage (5 g/m2 over 24 h), but otherwise the schedule is as above. In all 60 patients have been treated and most are now evaluable for response. Encephalopathy has been seen with both regimens. The incidence and patient characteristics are reported.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3102088&dopt=Abstract
Cancer Chemother Pharmacol. 1986;18 Suppl 2:S55-6.
Ifosfamide in advanced pancreatic cancer. A 5-year experience.
Gad-el-Mawla N.
Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo. Over five years, 25 patients received a daily dose of 1.8 g ifosfamide for five days, courses reported every 21 days. Complete remission was achieved in 1 patient and partial remission in 14 patients, an overall result of 60%, average duration of response being 12+ months. Mesna was used for uroprotection.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3102092&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||